



Australian Technical Advisory Group on Immunisation (ATAGI)

Summary of the 103rd meeting, 14 March 2024

Respiratory syncytial virus (RSV)

- ATAGI reviewed and discussed its draft statement on the clinical use of nirsevimab, a long-acting monoclonal antibody against RSV, as an immunisation strategy to prevent RSV in infants. This [statement](#) was published on 26 March 2024 on the Department of Health and Aged Care website.
- ATAGI reviewed and discussed the draft RSV chapter, which when finalised will be published in the [Australian Immunisation Handbook](#).

Departmental updates

- ATAGI received an update from the Therapeutic Goods Administration (TGA) on several vaccines that are currently under evaluation for registration in Australia.

Other business

- ATAGI noted that Ms Catherine Radkowski is no longer on the Jurisdictional Immunisation Committee and a new representative will be appointed to ATAGI. Members thanked Ms Radkowski for her contributions to ATAGI.

Resources

- ATAGI's membership, terms of reference and declaration of interest information is available on the [Department of Health and Aged Care website](#).